Antigens, CD274
-
Subject Areas on Research
- A Pan-Cancer Analysis of Enhancer Expression in Nearly 9000 Patient Samples.
- Activation of the PD-1 pathway contributes to immune escape in EGFR-driven lung tumors.
- Adaptive resistance to therapeutic PD-1 blockade is associated with upregulation of alternative immune checkpoints.
- An Analytical Comparison of Dako 28-8 PharmDx Assay and an E1L3N Laboratory-Developed Test in the Immunohistochemical Detection of Programmed Death-Ligand 1.
- Association and prognostic significance of BRCA1/2-mutation status with neoantigen load, number of tumor-infiltrating lymphocytes and expression of PD-1/PD-L1 in high grade serous ovarian cancer.
- Association of Polymerase e-Mutated and Microsatellite-Instable Endometrial Cancers With Neoantigen Load, Number of Tumor-Infiltrating Lymphocytes, and Expression of PD-1 and PD-L1.
- Atezolizumab: A PD-L1-Blocking Antibody for Bladder Cancer.
- B-cell receptor-mediated NFATc1 activation induces IL-10/STAT3/PD-L1 signaling in diffuse large B-cell lymphoma.
- B7-H1 expression in Wilms tumor: correlation with tumor biology and disease recurrence.
- B7-h1 as a biomarker for therapy failure in patients with favorable histology Wilms tumor.
- CEA/CD3-bispecific T cell-engaging (BiTE) antibody-mediated T lymphocyte cytotoxicity maximized by inhibition of both PD1 and PD-L1.
- Changes in tumour expression of programmed death-ligand 1 after neoadjuvant concurrent chemoradiotherapy in patients with squamous oesophageal cancer.
- Characteristics of Real-World Metastatic Non-Small Cell Lung Cancer Patients Treated with Nivolumab and Pembrolizumab During the Year Following Approval.
- Chemotherapy Induces Programmed Cell Death-Ligand 1 Overexpression via the Nuclear Factor-κB to Foster an Immunosuppressive Tumor Microenvironment in Ovarian Cancer.
- Clinical Significance of PTEN Deletion, Mutation, and Loss of PTEN Expression in De Novo Diffuse Large B-Cell Lymphoma.
- Combination Therapy with NHS-muIL12 and Avelumab (anti-PD-L1) Enhances Antitumor Efficacy in Preclinical Cancer Models.
- Combinations of Bevacizumab With Cancer Immunotherapy.
- Combined VEGF and PD-L1 Blockade Displays Synergistic Treatment Effects in an Autochthonous Mouse Model of Small Cell Lung Cancer.
- Comprehensive Characterization of Cancer Driver Genes and Mutations.
- First-Line Nivolumab in Stage IV or Recurrent Non-Small-Cell Lung Cancer.
- Identification of a soluble form of B7-H1 that retains immunosuppressive activity and is associated with aggressive renal cell carcinoma.
- Immune Biomarkers Predictive for Disease-Free Survival with Adjuvant Sunitinib in High-Risk Locoregional Renal Cell Carcinoma: From Randomized Phase III S-TRAC Study.
- Immune checkpoint blockade as a potential therapeutic target: surveying CNS malignancies.
- Immunomodulatory Activity of Nivolumab in Metastatic Renal Cell Carcinoma.
- Immunotherapy and Checkpoint Inhibitors in Recurrent and Metastatic Head and Neck Cancer.
- In Vitro Pre-Clinical Validation of Suicide Gene Modified Anti-CD33 Redirected Chimeric Antigen Receptor T-Cells for Acute Myeloid Leukemia.
- Increased expression of programmed death ligand 1 (PD-L1) in human pituitary tumors.
- Irradiation and immunotherapy: From concept to the clinic.
- Ly6Chi monocytes regulate T cell responses in viral hepatitis.
- Modification of host dendritic cells by microchimerism-derived extracellular vesicles generates split tolerance.
- Next steps in immuno-oncology: enhancing antitumor effects through appropriate patient selection and rationally designed combination strategies.
- Nivolumab for Metastatic Renal Cell Carcinoma: Results of a Randomized Phase II Trial.
- Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer.
- Nivolumab versus Docetaxel in Advanced Squamous-Cell Non-Small-Cell Lung Cancer.
- PD-1 expression and clinical PD-1 blockade in B-cell lymphomas.
- PD-1/PD-L1, but not PD-1/PD-L2, interactions regulate the severity of experimental autoimmune encephalomyelitis.
- PD-L1 (B7-H1) expression by urothelial carcinoma of the bladder and BCG-induced granulomata: associations with localized stage progression.
- PD-L1 expression is low in large B-cell lymphoma with MYC or double-hit translocation.
- PD-L1 inhibits acute and chronic pain by suppressing nociceptive neuron activity via PD-1.
- PD-L1 serves as a double agent in separating GVL from GVHD.
- PD-L1/B7H-1 inhibits the effector phase of tumor rejection by T cell receptor (TCR) transgenic CD8+ T cells.
- Prognostic role of tumoral PDL1 expression and peritumoral FoxP3+ lymphocytes in vulvar melanomas.
- Program death-1 immune checkpoint and tumor microenvironment in malignant liver tumors.
- Programmed death ligand 1 (PD-L1) as an immunotherapy target in patients with glioblastoma.
- STK11/LKB1 Deficiency Promotes Neutrophil Recruitment and Proinflammatory Cytokine Production to Suppress T-cell Activity in the Lung Tumor Microenvironment.
- Soluble B7-H1: differences in production between dendritic cells and T cells.
- Stromal Fibroblasts Mediate Anti-PD-1 Resistance via MMP-9 and Dictate TGFβ Inhibitor Sequencing in Melanoma.
- Surface expression patterns of negative regulatory molecules identify determinants of virus-specific CD8+ T-cell exhaustion in HIV infection.
- Systemic Immunotherapy of Non-Muscle Invasive Mouse Bladder Cancer with Avelumab, an Anti-PD-L1 Immune Checkpoint Inhibitor.
- Targetable Immune Regulatory Molecule Expression in High-Grade Serous Ovarian Carcinomas in African American Women: A Study of PD-L1 and IDO in 112 Cases From the African American Cancer Epidemiology Study (AACES).
- Targeting molecular and cellular inhibitory mechanisms for improvement of antitumor memory responses reactivated by tumor cell vaccine.
- Tolerance induced by apoptotic antigen-coupled leukocytes is induced by PD-L1+ and IL-10-producing splenic macrophages and maintained by T regulatory cells.
- Update: biomarkers for idiopathic inflammatory myopathies.